Marketing go-ahead for clot-breaking brush
This article was originally published in Clinica
The FDA has approved Micro Therapeutics' clot-breaking Cragg Thrombolytic Brush for use in the treatment of haemodialysis grafts. The brush is already marketed in Europe and Australia.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?